Terumo To Start U.S. Stent Trials
This article was originally published in PharmAsia News
Major Japanese medical device maker Terumo will start clinical trials for Misago, a peripheral self-expanding stent indicated for femoral and popliteal artery disease in the U.S and Japan within the year. The company launched the product in Europe aiming for ¥10 billion in annual sales. Last year, Terumo opened a Swiss location for the launch of Nobori, a new generation of drug-eluting stent used in patients suffering from coronary artery disease, and Misago. (Click here for more - Japanese language
You may also be interested in...
The EU pharmaceutical strategy published on 25 November will be the first step in a “complete overhaul” of the medicines legislative framework to be proposed in about two years’ time, says the European Commission.
The European Commission’s newly-published Pharmaceutical Strategy features a range of proposals related to generics and biosimilars, including “targeted policies” to improve competition, remove barriers and increase uptake.
Pfizer’s efforts to circumvent two US patents shielding Par’s Adrenalin (epinephrine) have again ended in failure, following a ruling by the US Court of Appeals for the Federal Circuit.